Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided once-daily intravenous busulfan conditioning before hematopoietic stem cell transplantation
jRCTs051200020Recruiting
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of busulfan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more. Primary endpoint: Progression-free survival at 24 months. Started Jun 2020; status: recruiting.
02
Drugs
busulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)myelofibrosis (MF)
Beyond the preview
Go deeper on jRCTs051200020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200020.